CTIS2024-515547-34-00进行中（未招募）1 期
on-inferiority study of a new therapeutic strategy for gout: immediate prescription of a hypouricemia treatment, febuxostat, compared to its deferred administration. FEFACRIGOU - 2017/0386/HP
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 128
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •Patients with an attack of gout, diagnosed immediately or less than 5 days old. Gout is defined according to American-European criteria (Appendix 3)., Attack of gout affecting one (or more) peripheral joint (s) whatever (s) it (s): • Either a first crisis, • Either a new attack of a gout not treated with a hypo-uricemic or for which the hypo-uricemic treatment has not been taken for at least 6 months., Uricemia = 420 µmol / l, including under a diuretic (dosage carried out within 10 days before inclusion),, Age = 18 years old, Patient with a creatinine clearance = 30 ml / min (dosage carried out within 10 days before inclusion), Patient having read and understood the information letter and signed the consent form, Affiliation to a social security scheme, Woman of childbearing potential with effective contraception according to WHO definition (estrogen-progestins or intrauterine device or tubal ligation for more than 1 month and to be continued for at least 5 weeks after the last dose of the drug. ) and a negative urine pregnancy test on inclusion and throughout the duration of the study., Postmenopausal woman: amenorrhea not medically induced for at least 12 months before the inclusion visit.
排除标准
- •Patients under the age of 18, Person with rare hereditary disorders of galactose intolerance, lactase deficiency or glucose / galactose malabsorption, Poor understanding of the project due to neurological disease or lack of French practice, Pregnant woman or likely to be in the absence of effective contraception (Women of childbearing age should have a negative urine pregnancy test), Breastfeeding woman, Any history of pre-existing major cardiovascular disease (myocardial infarction, stroke, unstable angina, etc.), metabolic, endocrine, psychiatric or cancerous in uncontrolled development, Person deprived of liberty by an administrative or judicial decision, Person placed under judicial protection, guardianship or curatorship, Participating patient who participated in the month preceding inclusion in another interventional drug trial, Stop taking a hypouricemic agent for less than 6 months, Known contraindication to ADENURIC 80 mg film-coated tablet: hypersensitivity to the active substance (febuxostat) or to one of the excipients, Renal failure defined by creatinine clearance <30 ml / min, Hepatic disease defined by an increase to more than 2 times the normal of transaminases, alkaline phosphatases, to more than 3 times the normal of gamma-GT, Non-weaned alcoholism, Crisis more than 5 days old, Patient who has received an organ or marrow transplant, Person on Naproxen, mercaptopurine, azathioprine, Glycuronidation inhibitors and inducers, theophylline, macrolides, HMG Co-A reductase inhibitors and / or diuretic in combination with an ACE inhibitor or ARAII
研究者
相似试验
暂停
3 期
Non-inferiority study of a new therapeutic strategy for gout: immediate prescription of a hypouricemia treatment, febuxostat, compared to its deferred administration.
FEFACRIGOU2024-515547-34-00Centre Hospitalier Universitaire Rouen128
进行中（未招募）
1 期
Evaluation d’une nouvelle stratégie thérapeutique chez des patients à fort risque évolutif, à la phase initiale de la sclérose en plaques : traitement séquentiel par mitoxantrone (Elsep 10mg/m² par mois pendant 6 mois) puis interféron bêta-1a (Rebif 44µg 3 fois par semaine) versus interféron bêta-1a seul. - 2MS1Sclérose en plaquesEUCTR2004-001601-10-FRCHRU Rennes266
已完成
不适用
Clinical trial aimed at new therapeutic strategy for HAM by prosultiamine treatment with oral administratioHTLV-I associated myelopathy (HAM)JPRN-UMIN000005969The Department of Molecular Microbiology and Immunology25
招募中
不适用
Wii Fit: the new generation tool for improving balance, health and well-being for women?Healthy AgeingBalancesedentary lifestylePhysical Medicine / Rehabilitation - PhysiotherapyACTRN12608000482369Jenny Nitz60
进行中（未招募）
1 期
CRA-TBETick-borne encephalitisMedDRA version: 21.1Level: LLTClassification code: 10077096Term: Tick-borne encephalitis immunization Class: 10042613CTIS2023-509575-16-00Vaestra Goetalandsregionen100